Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study

Daniel D. von Hoff; Thomas R. Fleming; John S. Macdonald; Phyllis J. Goodman; John Van Damme; Thomas D. Brown; Timothy O'Rourke; Lynn G. Feun; Michael D. Keppen

Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study

Daniel D. von Hoff, Thomas R. Fleming, John S. Macdonald, Phyllis J. Goodman, John Van Damme, Thomas D. Brown, Timothy O'Rourke, Lynn G. Feun, Michael D. Keppen

Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant γ-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. γ-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.

Original language	English (US)
Pages (from-to)	584-587
Number of pages	4
Journal	Journal of Biological Response Modifiers
Volume	9
Issue number	6
State	Published - Dec 1990

Keywords

γ-Interferon
Pancreatic cancer

ASJC Scopus subject areas

Cancer Research
Immunology
Pharmacology

Fingerprint Dive into the research topics of 'Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study'. Together they form a unique fingerprint.

Cite this

Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma : A southwest oncology group study. / von Hoff, Daniel D.; Fleming, Thomas R.; Macdonald, John S.; Goodman, Phyllis J.; Damme, John Van; Brown, Thomas D.; O'Rourke, Timothy; Feun, Lynn G.; Keppen, Michael D.

In: Journal of Biological Response Modifiers, Vol. 9, No. 6, 12.1990, p. 584-587.

Research output: Contribution to journal › Article › peer-review

von Hoff, Daniel D. ; Fleming, Thomas R. ; Macdonald, John S. ; Goodman, Phyllis J. ; Damme, John Van ; Brown, Thomas D. ; O'Rourke, Timothy ; Feun, Lynn G. ; Keppen, Michael D. / Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma : A southwest oncology group study. In: Journal of Biological Response Modifiers. 1990 ; Vol. 9, No. 6. pp. 584-587.

@article{8b60f3381b1046188494e289a2d4d9c6,

title = "Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study",

abstract = "Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant γ-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. γ-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.",

keywords = "γ-Interferon, Pancreatic cancer",

author = "{von Hoff}, {Daniel D.} and Fleming, {Thomas R.} and Macdonald, {John S.} and Goodman, {Phyllis J.} and Damme, {John Van} and Brown, {Thomas D.} and Timothy O'Rourke and Feun, {Lynn G.} and Keppen, {Michael D.}",

year = "1990",

month = dec,

language = "English (US)",

volume = "9",

pages = "584--587",

journal = "Journal of Immunotherapy",

issn = "1524-9557",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma

T2 - A southwest oncology group study

AU - von Hoff, Daniel D.

AU - Fleming, Thomas R.

AU - Macdonald, John S.

AU - Goodman, Phyllis J.

AU - Damme, John Van

AU - Brown, Thomas D.

AU - O'Rourke, Timothy

AU - Feun, Lynn G.

AU - Keppen, Michael D.

PY - 1990/12

Y1 - 1990/12

N2 - Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant γ-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. γ-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.

AB - Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant γ-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. γ-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.

KW - γ-Interferon

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0025694824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025694824&partnerID=8YFLogxK

M3 - Article

C2 - 2127424

AN - SCOPUS:0025694824

VL - 9

SP - 584

EP - 587

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -

Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A southwest oncology group study

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this